Bill Detail

H.R. 5629

Congress: 119

Title

To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.

Summary

This bill nullifies part of the final rule issued by the Department of Health and Human Services (HHS) titled Medications for the Treatment of Opioid Use Disorder and published on February 2, 2024. The rule incorporated into regulations certain flexibilities for opioid treatment that were initially implemented during the COVID-19 public health emergency. The bill nullifies these flexibilities, including (1) expanded flexibility for patients in their first or second month of treatment to receive take-home doses of methadone, (2) flexibility to use telehealth examinations to admit patients for treatment involving buprenorphine or methadone, and (3) expanded access to evidence-based practices such as splitting doses for certain patients. Pursuant to a statutory requirement, the rule also allowed patients to be admitted to an opioid treatment program without having to show at least a one-year history of opioid misuse. The bill nullifies these provisions of the rule.

Sponsor

Rep. Erin Houchin [R-IN-9]

Status

Referred to the House Committee on Energy and Commerce.

Status as of Jun 29, 10:32 AM · synced 10h ago

Introduced

2025-09-30

Data source mode: cache

Bill Engagement

Lobbyists on the case

5 orgs · 44 lobbyists · 5 filings mention H.R. 5629 (To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.) in LDA disclosures.